Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T71108 |
TLR7/8 agonist 1
|
||
TLR7/8 agonist 1是一种 toll 样受体 (TLR7)/TLR8的双重激动剂。 | |||
T5561 |
TLR7/8 agonist 1 dihydrochloride
TLR7/8 agonist-5d,二盐酸TLR7/8 agonist 1 |
TLR | Immunology/Inflammation |
TLR7/8 agonist 1 dihydrochloride (TLR7/8 agonist-5d) 是 toll 样受体TLR7/TLR8的双重激动剂。 | |||
T15371 |
Gardiquimod
|
TLR; HIV Protease | Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Gardiquimod 可抑制巨噬细胞和活化的外周血单个核细胞的HIV-1感染。 它是一种咪唑喹啉类似物,是一种 TLR7/8 激动剂。 | |||
T6964 |
Resiquimod
R848,雷西莫特,S28463 |
HCV Protease; TLR | Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
Resiquimod (R848) 是一种 Toll 样受体7/8的激动剂,可诱导细胞因子上调。 | |||
T60894 |
TLR7/8 agonist 4
|
||
TLR7/8 agonist 4 (compound 41) 是具有抗癌活性的,TLR7/8 的有效激动剂。 | |||
T79068 | TLR7/8 agonist 8 | ||
TLR7/8 agonist 8(compound 24m)是一种高效的TLR7/8双重激动剂,对hTLR7和hTLR8的EC50值分别为27 nM和12 nM。该化合物能增强PD-1/PD-L1阻断剂的抗癌效果。 | |||
T77890 |
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride
|
||
TLR7/8 agonist 4hydroxy-PEG6-acid hydrochloride为一种用于抗体药物偶联体(ADC)的药物-连接子偶联物。该化合物为TLR7/8 agonist 4hydroxy-PEG6-acid的盐酸盐形式,由TLR7/8 agonist 4与连接子 Hydroxy-PEG6-acid构成,适用于ADC合成。 | |||
T80976 | TLR7/8 agonist 4 hydroxy-PEG6-acid | ||
TLR7/8 agonist 4hydroxy-PEG6-acid 为ADC药物-连接子偶联物(Drug-Linker Conjugates for ADC)。该合成物结合了TLR7/8 agonist 4与连接子hydroxy-PEG6-acid,专门用于ADC合成。 | |||
T61601 | TLR7/8 antagonist 2 | ||
TLR7/8 antagonist 2 (Compound 15) is a highly potent and orally active agonist of TLR7/8, exhibiting IC50 values of 4.9 and 0.6 nM for TLR7 and TLR8, respectively. Its strong affinity for these receptors makes it a promising candidate for the treatment and investigation of autoimmune diseases, including lupus erythematosus, which is associated with inappropriate activation of TLR7 and TLR8. Consequently, TLR7/8 antagonist 2 represents a valuable tool for research in the field of autoimmune disea... | |||
T62178 | TLR7/8 antagonist 1 | ||
TLR7/8 Antagonist 1 (Compound 16c) 是一种咪唑喹啉衍生物,是一种有效的 TLR7/8 激动剂,对 TLR7 和 TLR8 的 IC50 值分别为 3.91 和 2.19 μM。其中 Toll 样受体 (TLR) 7 和 8 是一种治疗传染病、癌症和自身免疫性疾病的免疫调节药物开发的关键靶点。 | |||
T14035 |
3M-011
|
TLR | Immunology/Inflammation |
3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3]. | |||
T5499 |
gardiquimod TFA salt
|
||
Gardiquimod diTFA,咪唑啉类似物TLR7/8激动剂,可特异性抑制巨噬细胞和活化外周血单个核细胞(PBMCs)的HIV-1感染。在浓度低于10 μM时,该化合物特异性激活TLR7。 | |||
T79069 | TLR7/8 agonist 9 | ||
TLR7/8 agonist 9 (Compound 25a) 是一种能够增强PD-1/PD-L1阻断疗法抗肿瘤效果的化合物,主要用于癌症免疫疗法研究。它对hTLR7和hTLR8的EC50分别为40 nM和23 nM,显示出其对这两种受体的高亲和力以及潜在的抗肿瘤活性。 | |||
T61390 |
D18
|
||
D18 is an immune modulator that acts as a dual agonist for TLR7/8 (with EC50 values of 24 nM for hTLR7 and 10 nM for hTLR8, respectively). It enhances the expression of PD-L1 through epigenetic regulation, thereby increasing the sensitivity of tumors to PD-1/PD-L1 blockade. Additionally, D18 functions as a cytotoxin for ADC synthesis, specifically for the ADC HE-S2 [1]. | |||
T83895 |
NCI 126224
NSC 126224 |
||
NCI 126224 是一种 toll-like receptor 4 (TLR4) 的拮抗剂。它在 RAW 264.7 巨噬细胞中,选择性抑制由 TLR4 激动剂 LPS 引起的一氧化氮 (NO) 产生(IC50 = 0.31 µM),而对 TLR7/8 激动剂 R-848、TLR1/2 激动剂 Pam3CSK4 以及 TLR3 激动剂 poly(I:C) 的影响较小;但对于相同细胞中由 TLR2/6 激动剂 FSL-1 引起的 NO 产生,其抑制作用在 0.6 µM 时亦显现。此外,NCI 126224 在 BV-2 微胶质细胞的报告实验中抑制了 LPS 引起的 NF-κB 活性,并在 RAW 264.7 巨噬细胞中降低了 LPS 引起的 IL-1β 和 TNF-α 水平(IC50s = 5.92, 0.42, 和 1.54 µM,分别)。 |